Literature DB >> 14728688

Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates.

Sylvain M Cloutier1, Christoph Kündig, Loyse M Felber, Omar M Fattah, Jair R Chagas, Christian M Gygi, Patrice Jichlinski, Hans-Jürg Leisinger, David Deperthes.   

Abstract

The reactive site loop of serpins undoubtedly defines in part their ability to inhibit a particular enzyme. Exchanges in the reactive loop of serpins might reassign the targets and modify the serpin-protease interaction kinetics. Based on this concept, we have developed a procedure to change the specificity of known serpins. First, reactive loops are very good substrates for the target enzymes. Therefore, we have used the phage-display technology to select from a pentapeptide phage library the best substrates for the human prostate kallikrein hK2 [Cloutier, S.M., Chagas, J.R., Mach, J.P., Gygi, C.M., Leisinger, H.J. & Deperthes, D. (2002) Eur. J. Biochem. 269, 2747-2754]. Selected substrates were then transplanted into the reactive site loop of alpha1-antichymotrypsin to generate new variants of this serpin, able to inhibit the serine protease. Thus, we have developed some highly specific alpha1-antichymotrypsin variants toward human kallikrein 2 which also show high reactivity. These inhibitors might be useful to help elucidate the importance of hK2 in prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14728688     DOI: 10.1111/j.1432-1033.2003.03963.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

Review 1.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

2.  Evolution of cyclic peptide protease inhibitors.

Authors:  Travis S Young; Douglas D Young; Insha Ahmad; John M Louis; Stephen J Benkovic; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 3.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

Review 4.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

Review 5.  Emerging challenges in the design of selective substrates, inhibitors and activity-based probes for indistinguishable proteases.

Authors:  Paulina Kasperkiewicz; Marcin Poreba; Katarzyna Groborz; Marcin Drag
Journal:  FEBS J       Date:  2017-01-29       Impact factor: 5.542

6.  KLK-targeted Therapies for Prostate Cancer.

Authors:  Koistinen Hannu; Mattsson Johanna; Stenman Ulf-Håkan
Journal:  EJIFCC       Date:  2014-09-04

7.  An unexpected switch in peptide binding mode: from simulation to substrate specificity.

Authors:  Ursula Kahler; Julian E Fuchs; Peter Goettig; Klaus R Liedl
Journal:  J Biomol Struct Dyn       Date:  2018-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.